Preview: Clinical outcome and safety of rituximab therapy for pemphigoid diseases

Main Author:	Payne, Aimee S
Other Authors:	Tovanabutra, Napatra
Format:	Dataset
Terbitan:	Mendeley , 2020
Subjects:	Autoimmunity Rituximab Pemphigoid
Online Access:	https://doi.org/10.1016/j.jaad.2019.11.023 Supplemental materials for this retrospective case series including all (n=38) pemphigoid patients at the University of Pennsylvania followed at least 1 year after RTX or until death. Outcomes followed consensus definitions. The primary endpoint was complete remission (CR). Secondary endpoints were CR off therapy (CROT), corticosteroid dose, relapse, serious adverse events (SAEs), and autoantibody titers.